SCHEMBL3972288

SCHEMBL3972288

CC(=O)Nc1cc(-c2cncc(Br)c2)n(C)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 2/20 0.38
AOC3 Q16853 1/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
KMT2A Q03164 1/20 0.37
ADORA2A P29274 3/20 0.37
ADORA1 P30542 3/20 0.37
CYP3A4 P08684 2/20 0.37
MAP4K4 O95819 1/20 0.36
ABL1 P00519 1/20 0.36
MAPK8 P45983 1/20 0.36
CSNK1A1 P48729 1/20 0.36
CDK7 P50613 1/20 0.36
TYRO3 Q06418 1/20 0.36
LRRK2 Q5S007 1/20 0.36
AURKB Q96GD4 1/20 0.36
CLK4 Q9HAZ1 1/20 0.36
PIM2 Q9P1W9 1/20 0.36
DYRK1B Q9Y463 1/20 0.36
CYP1A2 P05177 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3974458 0.89 RAB9A (0.40) NPC1RAB9AKMT2APOLBHCAR2
SCHEMBL3972385 0.84 ADORA2A (0.37) AOC3KMT2AADORA2AADORA1CYP3A4
SCHEMBL4508178 0.79 PIP4K2A (0.48) AOC3PIK3C3PIK3CG
SCHEMBL10369 0.78 CYP1A2 (0.56) NPC1RAB9AADORA2AADORA1CYP3A4
SCHEMBL3971543 0.76 POLB (0.44) KMT2APOLBL3MBTL1HCAR2KDM4E
SCHEMBL3972438 0.76 MMP2 (0.44) PTGS2KMT2ACYP3A4CYP1A2
SCHEMBL3973580 0.74 ADORA1 (0.37) AOC3RAB9AADORA2AADORA1CYP3A4
SCHEMBL4511353 0.74 PIK3C3 (0.52) PIK3C3PIK3CG
SCHEMBL31200322 0.73 CYP2A6 (0.41) PTGS2NPC1RAB9APOLBKCNH2
SCHEMBL4506432 0.73 RAB9A (0.40) NPC1RAB9AKMT2AADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090118336-A1 PYRAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS ASTRAZENECA AB (SE) 2009-05-07 US disclosed
EP-2016068-A1 PYRAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS AstraZeneca AB (SE) 2009-01-21 EP disclosed
WO-2007129052-A1 PYRAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS ASTRAZENECA AB (SE) 2007-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118336-A1 PYRAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS MTOR, RICTOR, PIK3R5 PTGS2 1852/4885AOC3 3829/4885NPC1 1313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.